JP2002532392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002532392A5 JP2002532392A5 JP2000587608A JP2000587608A JP2002532392A5 JP 2002532392 A5 JP2002532392 A5 JP 2002532392A5 JP 2000587608 A JP2000587608 A JP 2000587608A JP 2000587608 A JP2000587608 A JP 2000587608A JP 2002532392 A5 JP2002532392 A5 JP 2002532392A5
- Authority
- JP
- Japan
- Prior art keywords
- mecamylamine
- exo
- pharmaceutical composition
- weight
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002525 mecamylamine Drugs 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960001263 mecamylamine hydrochloride Drugs 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11253498P | 1998-12-16 | 1998-12-16 | |
| US60/112,534 | 1998-12-16 | ||
| PCT/US1999/030153 WO2000035279A1 (en) | 1998-12-16 | 1999-12-16 | Exo-s-mecamylamine formulation and use in treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011055716A Division JP2011126909A (ja) | 1998-12-16 | 2011-03-14 | エキソ−ｓ−メカミラミン製剤および治療におけるその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002532392A JP2002532392A (ja) | 2002-10-02 |
| JP2002532392A5 true JP2002532392A5 (https=) | 2007-02-08 |
Family
ID=22344414
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000587609A Withdrawn JP2002532393A (ja) | 1998-12-16 | 1999-12-16 | エキソ−ｒ−メカミラミン製剤および治療におけるその使用 |
| JP2000587608A Pending JP2002532392A (ja) | 1998-12-16 | 1999-12-16 | エキソ−ｓ−メカミラミン製剤および治療におけるその使用 |
| JP2011055716A Withdrawn JP2011126909A (ja) | 1998-12-16 | 2011-03-14 | エキソ−ｓ−メカミラミン製剤および治療におけるその使用 |
| JP2013258032A Pending JP2014051528A (ja) | 1998-12-16 | 2013-12-13 | エキソ−ｓ−メカミラミン製剤および治療におけるその使用 |
| JP2016011658A Pending JP2016065108A (ja) | 1998-12-16 | 2016-01-25 | エキソ−ｓ−メカミラミン製剤および治療におけるその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000587609A Withdrawn JP2002532393A (ja) | 1998-12-16 | 1999-12-16 | エキソ−ｒ−メカミラミン製剤および治療におけるその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011055716A Withdrawn JP2011126909A (ja) | 1998-12-16 | 2011-03-14 | エキソ−ｓ−メカミラミン製剤および治療におけるその使用 |
| JP2013258032A Pending JP2014051528A (ja) | 1998-12-16 | 2013-12-13 | エキソ−ｓ−メカミラミン製剤および治療におけるその使用 |
| JP2016011658A Pending JP2016065108A (ja) | 1998-12-16 | 2016-01-25 | エキソ−ｓ−メカミラミン製剤および治療におけるその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20020016370A1 (https=) |
| EP (3) | EP1139743B1 (https=) |
| JP (5) | JP2002532393A (https=) |
| AT (2) | ATE320711T1 (https=) |
| AU (2) | AU2368600A (https=) |
| CA (2) | CA2393437C (https=) |
| CY (1) | CY1108577T1 (https=) |
| DE (2) | DE69939498D1 (https=) |
| DK (2) | DK1634498T3 (https=) |
| ES (2) | ES2313187T3 (https=) |
| PT (2) | PT1634498E (https=) |
| WO (2) | WO2000035279A1 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| ES2285233T3 (es) | 2002-12-20 | 2007-11-16 | Niconovum Ab | Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable. |
| ES2294480T3 (es) * | 2003-03-14 | 2008-04-01 | Agi Therapeutics Research Limited | Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina. |
| US20070224284A1 (en) * | 2004-03-12 | 2007-09-27 | John Devane | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
| DE10318714B4 (de) * | 2003-04-25 | 2006-03-23 | Hf Arzneimittelforschung Gmbh | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches |
| JP5254616B2 (ja) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達 |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| CA2633655A1 (en) * | 2005-12-19 | 2007-07-05 | Comentis, Inc. | Topical mecamylamine formulations for ocular administration and uses therof |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
| CL2007002903A1 (es) * | 2006-10-09 | 2008-04-18 | Smithkline Beecham Corp | Composicion que comprende a) al menos un antagonista del receptor nicotinico a3beta4; y b) al menos un metabolito de la nicotina; y uso para reducir los sintomas de abstinencia de nicotina y/o el uso del tabaco. |
| US20080242947A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Configuring software for effective health monitoring or the like |
| US20090119154A1 (en) * | 2007-11-07 | 2009-05-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content |
| US20090018407A1 (en) * | 2007-03-30 | 2009-01-15 | Searete Llc, A Limited Corporation Of The State Of Delaware | Computational user-health testing |
| US20090005654A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080243005A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242948A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
| US20090005653A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080242952A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liablity Corporation Of The State Of Delaware | Effective response protocols for health monitoring or the like |
| US20080242951A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
| US20080242949A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| US20080319276A1 (en) * | 2007-03-30 | 2008-12-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
| EP2322168A1 (en) | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
| WO2009143403A1 (en) * | 2008-05-23 | 2009-11-26 | Targacept, Inc. | Combination therapy for the management hypertension |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| CN102548550A (zh) * | 2009-07-14 | 2012-07-04 | 塔加西普特公司 | 外型-s-美卡拉明用于治疗的方法、用途和化合物 |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| PE20130775A1 (es) * | 2010-05-27 | 2013-07-21 | Targacept Inc | Antagonistas no competitivos de receptores nicotinicos |
| EP2672847B1 (de) | 2011-02-11 | 2015-04-22 | Batmark Limited | Inhalatorkomponente |
| AT510837B1 (de) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| KR102196913B1 (ko) | 2011-09-06 | 2020-12-30 | 니코벤처스 트레이딩 리미티드 | 가열식 흡연가능 재료 |
| KR101752639B1 (ko) | 2011-09-06 | 2017-06-30 | 브리티시 아메리칸 토바코 (인베스트먼츠) 리미티드 | 가열식 끽연 가능 물질 |
| AT511344B1 (de) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| US8901177B2 (en) * | 2012-03-23 | 2014-12-02 | Targacept, Inc. | Method of treating bladder disorders |
| GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
| GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| GB2504075A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
| GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
| GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
| EP3182967B1 (en) * | 2014-08-22 | 2021-05-26 | Atacama Therapeutics, Inc. | Dexmecamylamine for use in the treatment of hyperhidrosis |
| GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| GB201505597D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Article for use with apparatus for heating smokable material |
| GB201505595D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Cartridge for use with apparatus for heating smokeable material |
| GB201511361D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic vapour provision system |
| GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
| US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
| US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
| WO2017187148A1 (en) | 2016-04-27 | 2017-11-02 | Nicoventures Holdings Limited | Electronic aerosol provision system and vaporizer therefor |
| EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| EP3801732A4 (en) | 2018-05-29 | 2022-04-27 | Morningside Venture Investments Limited | METHODS AND SYSTEMS FOR DRUG DELIVERY |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| GB202203728D0 (en) * | 2022-03-17 | 2022-05-04 | Univ Oxford Innovation Ltd | Treatments and methods for increasing dopamine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5039801A (en) * | 1985-12-20 | 1991-08-13 | The United States Of America As Represented By The Department Of Health & Human Services | Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines |
| US4749686A (en) * | 1986-12-04 | 1988-06-07 | New York Medical College | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases |
| DE3887591T2 (de) * | 1987-07-07 | 1994-05-19 | Beecham Group Plc | Pinacidil zur Behandlung von pulmonaler Hypertonie oder Rechtsversagen. |
| US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
-
1999
- 1999-12-16 CA CA002393437A patent/CA2393437C/en not_active Expired - Fee Related
- 1999-12-16 JP JP2000587609A patent/JP2002532393A/ja not_active Withdrawn
- 1999-12-16 AT AT99967401T patent/ATE320711T1/de active
- 1999-12-16 PT PT05024899T patent/PT1634498E/pt unknown
- 1999-12-16 AU AU23686/00A patent/AU2368600A/en not_active Abandoned
- 1999-12-16 JP JP2000587608A patent/JP2002532392A/ja active Pending
- 1999-12-16 ES ES05024899T patent/ES2313187T3/es not_active Expired - Lifetime
- 1999-12-16 EP EP99967401A patent/EP1139743B1/en not_active Expired - Lifetime
- 1999-12-16 PT PT99967401T patent/PT1139743E/pt unknown
- 1999-12-16 WO PCT/US1999/030153 patent/WO2000035279A1/en not_active Ceased
- 1999-12-16 CA CA002393442A patent/CA2393442A1/en not_active Abandoned
- 1999-12-16 DE DE69939498T patent/DE69939498D1/de not_active Expired - Lifetime
- 1999-12-16 EP EP99967396A patent/EP1139744A4/en not_active Withdrawn
- 1999-12-16 AU AU23682/00A patent/AU2368200A/en not_active Abandoned
- 1999-12-16 DE DE69930552T patent/DE69930552T2/de not_active Expired - Lifetime
- 1999-12-16 EP EP05024899A patent/EP1634498B1/en not_active Expired - Lifetime
- 1999-12-16 DK DK05024899T patent/DK1634498T3/da active
- 1999-12-16 DK DK99967401T patent/DK1139743T3/da active
- 1999-12-16 ES ES99967401T patent/ES2260959T3/es not_active Expired - Lifetime
- 1999-12-16 AT AT05024899T patent/ATE406797T1/de active
- 1999-12-16 WO PCT/US1999/030137 patent/WO2000035280A1/en not_active Ceased
-
2001
- 2001-06-15 US US09/882,934 patent/US20020016370A1/en not_active Abandoned
-
2008
- 2008-11-19 CY CY20081101333T patent/CY1108577T1/el unknown
-
2011
- 2011-03-14 JP JP2011055716A patent/JP2011126909A/ja not_active Withdrawn
-
2013
- 2013-12-13 JP JP2013258032A patent/JP2014051528A/ja active Pending
-
2016
- 2016-01-25 JP JP2016011658A patent/JP2016065108A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002532392A5 (https=) | ||
| CA2393437A1 (en) | Exo-s-mecamylamine formulation and use in treatment | |
| ES2617628T5 (es) | Régimen de dosificación para un agonista selectivo del receptor de S1P1 | |
| JP2005515966A5 (https=) | ||
| EP2746251A3 (en) | Positively charged water-soluble prodrugs of acetaminophen and related compunds with very fast skin penetration rate | |
| JP2005520778A5 (https=) | ||
| JP2005515966A (ja) | 鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与 | |
| JP2002541097A (ja) | 線維筋痛症及び関連症状の治療におけるフルピルチン | |
| CN1856339A (zh) | 肺动脉高血压症治疗的伊洛前列素联合疗法 | |
| JP2003519228A5 (https=) | ||
| CN102753158A (zh) | 抗痴呆药物的经皮吸收制剂 | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2006513184A5 (https=) | ||
| TWI325320B (en) | Active ingredient combination for pharmacological addictive substance or intoxicant therapy | |
| JP2005508872A5 (https=) | ||
| JP2001520994A5 (https=) | ||
| JP2009517411A5 (https=) | ||
| SK138095A3 (en) | Transdermal therapeutic system for the administration of serotonin agonists | |
| JP2002544227A5 (https=) | ||
| JP2006514681A5 (https=) | ||
| JP4287596B2 (ja) | ニコチン依存症の治療のためのデオキシペガニン含有医薬組成物 | |
| JP2016505050A5 (https=) | ||
| JP2003176227A (ja) | 製薬組成物、喫煙を控えている患者の喫煙禁断症状を軽減する方法及び患者の喫煙禁断症状を軽減するキット | |
| JP2021535163A5 (https=) | ||
| JP2003523385A5 (https=) |